You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康臣藥業(1681.HK):支持新疆霍爾果斯創新發展,中醫藥產業園成效顯著
格隆匯 11-15 18:49

康臣藥業(霍爾果斯)有限公司是一家從事現代中成藥研發、生產及銷售的現代化製藥企業,成立於2020年,是香港主板上市公司康臣藥業(1681.HK)集團旗下全資子公司。項目總投資10億元,標準廠房建築面積2.7萬平方米,主要建設以尿毒清為主力品種的藥品研發、生產、銷售為一體的中醫藥產業園項目。

康臣藥業(霍爾果斯)有限公司充分利用大西北豐富藥材資源的成本優勢,輻射中亞五國的地緣優勢以及企業所得税五免五減的税收優惠政策。在當地政府和相關部門的的大力支持下,康臣藥業(霍爾果斯)有限公司為解決建設期間產品市場需求,採取邊建設、邊委託生產、銷售的模式運營,目前己實現產值超過4億元,銷售收入超過2億元。

除此之外,各級政府還配套了各類扶持政策和獎勵辦法,對重大項目實行“一事一議”“特事特辦”,極大地提高了企業投資的積極性,保證了項目建設的順利開展。接下來,該公司還將根據當地的有利資源和政策,不斷投入新的中成藥品種,促進霍爾果斯經濟高質量發展,實現政商互促,政企共贏。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account